Mona Ashiya Sells 83,182 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) Director Mona Ashiya sold 83,182 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90. Following the completion of the sale, the director now owns 194,209 shares in the company, valued at approximately $10,574,680.05. This represents a 29.99 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Mona Ashiya also recently made the following trade(s):

• On Monday, March 10th, Mona Ashiya sold 202,146 shares of Disc Medicine stock. The shares were sold at an average price of $54.29, for a total transaction of $10,974,506.34.

Disc Medicine Stock Performance

Disc Medicine stock opened at $52.41 on Friday. The stock has a market capitalization of $1.81 billion, a P/E ratio of -13.17 and a beta of 0.73. The company’s fifty day moving average price is $56.62 and its 200 day moving average price is $55.94. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $68.86.

Disc Medicine (NASDAQ:IRON) last announced its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.08. Sell-side analysts predict that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Wall Street Analysts Forecast Growth

IRON has been the subject of a number of recent research reports. Wedbush reiterated an “outperform” rating and set a $90.00 price objective (up previously from $83.00) on shares of Disc Medicine in a research note on Tuesday, January 21st. Morgan Stanley reiterated an “overweight” rating and set a $85.00 price target on shares of Disc Medicine in a research report on Friday, March 7th. Stifel Nicolaus upped their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research report on Friday, January 24th. TD Cowen began coverage on shares of Disc Medicine in a report on Thursday, February 27th. They set a “buy” rating for the company. Finally, Scotiabank boosted their target price on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $89.10.

Institutional Investors Weigh In On Disc Medicine

Several large investors have recently bought and sold shares of IRON. FMR LLC raised its stake in Disc Medicine by 358.7% in the 4th quarter. FMR LLC now owns 1,866,248 shares of the company’s stock valued at $118,320,000 after purchasing an additional 1,459,434 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Disc Medicine by 4.8% in the third quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock valued at $90,429,000 after buying an additional 83,731 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Disc Medicine by 23.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,394,637 shares of the company’s stock worth $88,421,000 after buying an additional 262,690 shares in the last quarter. Janus Henderson Group PLC boosted its position in Disc Medicine by 62.4% during the fourth quarter. Janus Henderson Group PLC now owns 1,217,815 shares of the company’s stock worth $77,170,000 after acquiring an additional 467,988 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Disc Medicine by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 1,068,246 shares of the company’s stock valued at $67,727,000 after acquiring an additional 18,716 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.